The estimated Net Worth of David W Meline is at least 6.99 百万$ dollars as of 6 March 2024. Mr Meline owns over 40,000 units of Moderna Inc stock worth over 3,180,400$ and over the last 16 years he sold MRNA stock worth over 2,878,614$. In addition, he makes 932,618$ as CFO & Principal Accounting Officer at Moderna Inc.
Mr has made over 16 trades of the Moderna Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of MRNA stock worth 176,000$ on 6 March 2024.
The largest trade he's ever made was buying 40,000 units of Moderna Inc stock on 6 March 2024 worth over 176,000$. On average, Mr trades about 1,815 units every 90 days since 2009. As of 6 March 2024 he still owns at least 40,000 units of Moderna Inc stock.
You can see the complete history of Mr Meline stock trades at the bottom of the page.
David W. Meline is the CFO & Principal Accounting Officer at Moderna Inc.
As the CFO & Principal Accounting Officer of Moderna Inc, the total compensation of Mr Meline at Moderna Inc is 932,618$. There are 9 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of 8,948,210$.
Mr Meline is 64, he's been the CFO & Principal Accounting Officer of Moderna Inc since . There are 1 older and 17 younger executives at Moderna Inc. The oldest executive at Moderna Inc is Elizabeth Tallett, 71, who is the Director.
David's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Over the last 6 years, insiders at Moderna Inc have traded over 2,713,086,305$ worth of Moderna Inc stock and bought 52,631 units worth 999,989$ . The most active insiders traders include Noubar Afeyan、David M. Rubenstein、Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of 2,841,687$. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth 90,562$.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: